PATENT CLAIM ANALYSIS

Application Number: 16119362
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-08
Patent Classification: ["424", "461000"]

Abstract:
Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-released solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention related to a methods of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowl disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

Claim (Index 1):
A controlled-release solid dosage form, comprising a plurality of mini-tablets, wherein each mini-tablet comprises:\n (a) a core, comprising mesalamine; and (b) a coating, comprising low-viscosity ethyl cellulose; and a pore-forming agent selected from the group consisting of hydroxypropyl cellulose and hydroxypropyl methylcellulose; wherein the coating surrounds the core.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 96.0
- Lexical Diversity: 1.90909
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14383462', '12573081', '10943356', '15292300', '14857933']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6580656804378566
- 35 USC 102 Novelty (BERT): 0.5396506949181821
- Combined Prediction Score: 0.6462241818858893
- Mean Citation Score: 213.318554
- Max Citation Score: 383.0397
- Similarity Product: 303.6993570382655

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test